Osivax raises €33m from EIC and BPI France

EIC contributed €17.5m while BPI France provided the remaining €15.1m. 

BPI France's contribution is a grant to support Osivax's coronavirus vaccine programme.

About €2.5m from EIC's contribution will be used to support the completion of the company's phase-IIa immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate, with €15m to be counted as equity towards Osivax's series-B fundraising.

The company, founded three years ago, will use the proceeds to develop universal coronavirus and influenza vaccines. OligoDOM, the company's proprietary technology, helps to develop vaccines that can fight all viral influenza strains.

Osivax has so far raised €44m in equity funding as well as grants. 

Previous Funding
In 2017, Osivax raised €2.7m in seed funding from Pradeyrol Développement and other family offices. This was followed by a €8m series-A round led by Belgian investment firm Noshaq, previously known as Meusinvest, and joined by Anaxago, an innovative investment platform that enables individuals to participate in fundraising for early-stage companies through a holding company. 

Company
Founded in 2017 and headquartered in Lyon, France, and Liege, Belgium, Osivax is a biotechnology company developing a vaccine to fight viral influenza strains, including Sars‑Cov‑2. According to its LinkedIn profile, the company employs fewer than 50 employees.

People
Osivax – Alexandre Le Vert (CEO)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Venture
• France
• BPI France